Published in Biologics on September 01, 2008
Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol (2010) 0.96
Enhancement of the efficacy of cancer chemotherapy by the pineal hormone melatonin and its relation with the psychospiritual status of cancer patients. J Res Med Sci (2010) 0.81
Endoglin Is Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells. Stem Cell Reports (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Renal-cell carcinoma. N Engl J Med (1996) 11.46
Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol (2007) 11.04
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med (1999) 9.18
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 9.05
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun (1989) 7.39
Isolation of a tumor factor responsible for angiogenesis. J Exp Med (1971) 7.12
Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest (2006) 6.12
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet (1999) 4.72
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer (2008) 4.41
A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res (1986) 4.12
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun (2005) 4.06
Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) 3.88
The epidemiology of renal cell carcinoma. J Urol (2006) 3.85
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol (2003) 3.66
VEGF as a key mediator of angiogenesis in cancer. Oncology (2005) 3.65
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest (1995) 3.52
The genetic basis of cancer of the kidney. J Urol (2003) 3.45
Renal cell carcinoma guideline. Eur Urol (2007) 3.42
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res (2001) 2.78
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol (2007) 2.69
Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med (1998) 2.64
Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol (1999) 2.45
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer (2003) 2.40
The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun (2005) 2.37
Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist (2001) 2.22
The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res (2007) 2.19
Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol (2008) 1.91
The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors (1992) 1.84
Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int (2004) 1.79
Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol (2002) 1.76
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol (2001) 1.58
Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res (2007) 1.57
Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer (2009) 1.56
The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int (2008) 1.49
Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie (2007) 1.48
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol (2007) 1.32
The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J (2000) 1.24
The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med (2003) 1.23
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol (2008) 1.18
Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res (2004) 1.16
Immunotherapy for renal cell cancer. J Clin Oncol (2006) 1.11
Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology (2007) 1.08
Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol (2006) 1.08
Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol (2006) 1.04
Interferon in metastatic renal cell carcinoma. Semin Oncol (2000) 0.99
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies. BJU Int (2007) 0.97
Renal cancer. Crit Rev Oncol Hematol (2007) 0.96
Immunotherapy for metastatic renal cell carcinoma. BJU Int (2007) 0.88
Evaluation of microvessel density by computerised image analysis in human renal cell carcinoma. Correlation to pT category, nuclear grade, proliferative activity and occurrence of metastasis. J Cancer Res Clin Oncol (1998) 0.82
Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. ScientificWorldJournal (2007) 0.81
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers. Curr Drug Targets (2011) 0.97
Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. Expert Rev Anticancer Ther (2008) 0.92